The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...

The Food and Drug Administration has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for ...

Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly’s lead in obesity and diabetes treatment should hold ...

The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?

The first pills are expected to hit the market next month and attract people who don’t want to give themselves shots.

There’s “quite big news” around weight loss medications circulating right now, says Wajahat Mehal, MD, director of Yale ...

After a year that has been anything but smooth sailing, pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is closing out 2025 on a positive note. Shares received a significant 7% boost on Dec. 23.

In the studies the company submitted to the FDA, people who took the daily Wegovy pill lost about the same amount of ...

The FDA on Monday approved a daily pill version of Novo Nordisk’s Wegovy, making it the first oral GLP-1 obesity treatment ...

The FDA has approved the first-ever Wegovy pill for weight loss, with the oral GLP-1 offering a 16.6% average weight ...

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine ...

The FDA has approved a pill form of the popular GLP-1 weight-loss medication Wegovy. Novo Nordisk says it is as effective as ...